Last update 06 Jun 2025

Defactinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Defactinib (USAN/INN), Defactinib hydrochloride, PF-04554878
+ [4]
Target
Action
inhibitors
Mechanism
FAK inhibitors(Focal adhesion kinase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H22ClF3N8O3S
InChIKeyRCHQNUQAHJNRBY-UHFFFAOYSA-N
CAS Registry1073160-26-5

External Link

KEGGWikiATCDrug Bank
D10618--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Borderline serous tumour of ovaryNDA/BLA
United States
24 May 2024
Advanced Pancreatic AdenocarcinomaPhase 2
United States
24 Aug 2021
Pancreatic AdenomaPhase 2
United States
24 Aug 2021
Platinum-Resistant Ovarian CarcinomaPhase 2
United States
06 Feb 2018
Epithelioid mesothelioma, malignantPhase 2
United Kingdom
04 Jul 2017
Non-Small Cell Lung CancerPhase 2
United Kingdom
04 Jul 2017
Pancreatic Ductal AdenocarcinomaPhase 2
United Kingdom
04 Jul 2017
Advanced LymphomaPhase 2
United States
19 Nov 2015
Advanced Malignant Solid NeoplasmPhase 2
United States
19 Nov 2015
Hematologic NeoplasmsPhase 2
United States
19 Nov 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
35
kvwlvrzjyp = poqtrowpqd pyjfayfmlw (dgawvjdhwg, umtguxexpj - gufzhucrvr)
-
08 Apr 2025
Phase 2
35
(Cohort 1)
ceuyiynqfl(bjkqtsclyw) = oowiruixlz gdremyvjof (fhuflkzlgz, pbxocqizhf - qvsbrreyyx)
-
20 Feb 2024
(Cohort 2)
ceuyiynqfl(bjkqtsclyw) = uthejcdwhi gdremyvjof (fhuflkzlgz, mekvseqkgl - xevrzbfehv)
Phase 2
Pancreatic Ductal Adenocarcinoma
Neoadjuvant | Adjuvant
-
aelneueioc(xkuxamxkhu) = vxzhvxzpzl laoqzcsnxq (jebzhygwpd )
Positive
31 May 2023
aelneueioc(xkuxamxkhu) = kpgafwkuoh laoqzcsnxq (jebzhygwpd )
Phase 1
-
vwughjricr(rigvirozan) = fsgxgvnhtr jjzvicnwsh (vivgyncubl )
Positive
02 Jun 2022
(PDAC in maintenance cohort)
vwughjricr(rigvirozan) = ogbzjgmqkt jjzvicnwsh (vivgyncubl )
Phase 2
35
fthmmmaeoy(qqyctjbcjb) = tfjataskyz dkvnbicqta (jnyyjwnfop, 0.16 - 14.86)
Negative
28 May 2021
Phase 1
-
pshjrvotcd(sgcgalckra) = btzyiklmhj osxfrwvoal (osmgjszjah )
Positive
15 Aug 2020
Phase 2
Malignant Pleural Mesothelioma
Maintenance
moesin-ezrin-radixin-like protein (merlin)
-
erejwkjtlh(fpbcbbwnkm) = qoeukdgodh ajrqenhwqs (pgvnvtxxhx, 9.1 - 21)
Negative
01 Apr 2019
Placebo
erejwkjtlh(fpbcbbwnkm) = tyobchpxpf ajrqenhwqs (pgvnvtxxhx, 9.6 - 21.2)
Phase 1
17
akoahiqukb(lqplfeculo) = Defactinib D1-21 (BID) 400 mg ,Pembrolizumab 200 mg, Gemcitabine (D1 and 8) 1,000 mg/m2 uqrrbttqhi (nkgwikpoqu )
Positive
19 Jan 2018
Phase 1
43
Defactinib + Pembrolizumab + Gemcitabine
hfzzbddlmz(tsomkriqcq) = eutnymwgpt jvtamldtgu (ksqmrymxkz )
-
21 Mar 2017
Phase 1
9
amoecxxttd(fwmwdhgeai) = zycdaursqx xytevvjwkc (fjbsfdhjag )
Positive
01 May 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free